|
1
|
Kufe DW: Mucins in cancer: function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duffy MJ: CA 15-3 and related mucins as
circulating markers in breast cancer. Ann Clin Biochem. 36(Pt 5):
579–586. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Apostolopoulos V, Pietersz GA, Tsibanis A,
et al: Pilot phase III immunotherapy study in early-stage breast
cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast
Cancer Res. 8:R272006.
|
|
4
|
Sugiura D, Aida S, Denda-Nagai K, et al:
Differential effector mechanisms induced by vaccination with MUC1
DNA in the rejection of colon carcinoma growth at orthotopic sites
and metastases. Cancer Sci. 99:2477–2484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang S, Zhang HS, Cordon-Cardo C,
Ragupathi G and Livingston PO: Selection of tumor antigens as
targets for immune attack using immunohistochemistry: protein
antigens. Clin Cancer Res. 4:2669–2676. 1998.PubMed/NCBI
|
|
6
|
Gendler S, Taylor-Papadimitriou J, Duhig
T, Rothbard J and Burchell J: A highly immunogenic region of a
human polymorphic epithelial mucin expressed by carcinomas is made
up of tandem repeats. J Biol Chem. 263:12820–12823. 1988.PubMed/NCBI
|
|
7
|
Ligtenberg MJ, Kruijshaar L, Buijs F, van
Meijer M, Litvinov SV and Hilkens J: Cell-associated episialin is a
complex containing two proteins derived from a common precursor. J
Biol Chem. 267:6171–6177. 1992.PubMed/NCBI
|
|
8
|
Kufe DW: Targeting the human MUC1
oncoprotein: a tale of two proteins. Cancer Biol Ther. 7:81–84.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh PK and Hollingsworth MA: Cell
surface-associated mucins in signal transduction. Trends Cell Biol.
16:467–476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carraway KL III, Funes M, Workman HC and
Sweeney C: Contribution of membrane mucins to tumor progression
through modulation of cellular growth signaling pathways. Curr Top
Dev Biol. 78:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu LG, Andrews N, Zhao Q, et al:
Galectin-3 interaction with Thomsen-Friedenreich disaccharide on
cancer-associated MUC1 causes increased cancer cell endothelial
adhesion. J Biol Chem. 282:773–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rahn JJ, Shen Q, Mah BK and Hugh JC: MUC1
initiates a calcium signal after ligation by intercellular adhesion
molecule-1. J Biol Chem. 279:29386–29390. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahn JJ, Chow JW, Horne GJ, et al: MUC1
mediates transendothelial migration in vitro by ligating
endothelial cell ICAM-1. Clin Exp Metastasis. 22:475–483. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen Q, Rahn JJ, Zhang J, et al: MUC1
initiates Src-CrkL- Rac1/Cdc42-mediated actin cytoskeletal
protrusive motility after ligating intercellular adhesion
molecule-1. Mol Cancer Res. 6:555–567. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Q, Barclay M, Hilkens J, et al:
Interaction between circulating galectin-3 and cancer-associated
MUC1 enhances tumour cell homotypic aggregation and prevents
anoikis. Mol Cancer. 9:1542010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang L, Chen D, Liu D, Yin L, Kharbanda S
and Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase
3beta-mediated phosphorylation and degradation of beta-catenin.
Cancer Res. 65:10413–10422. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Kuwahara H, Ren J, Wen G and Kufe D:
The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1
carcinoma-associated antigen with GSK3 beta and beta-catenin. J
Biol Chem. 276:6061–6064. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pandey P, Kharbanda S and Kufe D:
Association of the DF3/MUC1 breast cancer antigen with Grb2 and the
Sos/Ras exchange protein. Cancer Res. 55:4000–4003. 1995.PubMed/NCBI
|
|
19
|
Wei X, Xu H and Kufe D: Human mucin 1
oncoprotein represses transcription of the p53 tumor suppressor
gene. Cancer Res. 67:1853–1858. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh PK, Behrens ME, Eggers JP, et al:
Phosphorylation of MUC1 by Met modulates interaction with p53 and
MMP1 expression. J Biol Chem. 283:26985–26995. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schroeder JA, Thompson MC, Gardner MM and
Gendler SJ: Transgenic MUC1 interacts with epidermal growth factor
receptor and correlates with mitogen-activated protein kinase
activation in the mouse mammary gland. J Biol Chem.
276:13057–13064. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lau SK, Shields DJ, Murphy EA, et al:
EGFR-mediated carcinoma cell metastasis mediated by integrin
alphavbeta5 depends on activation of c-Src and cleavage of MUC1.
PLoS One. 7:e367532012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ahmad R, Raina D, Trivedi V, et al: MUC1
oncoprotein activates the IkappaB kinase beta complex and
constitutive NF-kappaB signalling. Nat Cell Biol. 9:1419–1427.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahmad R, Raina D, Joshi MD, et al: MUC1-C
oncoprotein functions as a direct activator of the nuclear
factor-kappaB p65 transcription factor. Cancer Res. 69:7013–7021.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu XF, Yang E, Li J and Xing PX: MUC1
cytoplasmic tail: a potential therapeutic target for ovarian
carcinoma. Expert Rev Anticancer Ther. 6:1261–1271. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kufe DW: Functional targeting of the MUC1
oncogene in human cancers. Cancer Biol Ther. 8:1197–1203. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Klinge CM, Radde BN, Imbert-Fernandez Y,
et al: Targeting the intracellular MUC1 C-terminal domain inhibits
proliferation and estrogen receptor transcriptional activity in
lung adenocarcinoma cells. Mol Cancer Ther. 10:2062–2071. 2011.
View Article : Google Scholar
|
|
28
|
Hattrup CL, Bradley JM, Kotlarczyk KL, et
al: The MUC1 cytoplasmic tail and tandem repeat domains contribute
to mammary oncogenesis in FVB mice. Breast Cancer (Auckl). 1:57–63.
2008.PubMed/NCBI
|
|
29
|
Wang L, Ma J, Liu F, et al: Expression of
MUC1 in primary and metastatic human epithelial ovarian cancer and
its therapeutic significance. Gynecol Oncol. 105:695–702. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kohlgraf KG, Gawron AJ, Higashi M, et al:
Contribution of the MUC1 tandem repeat and cytoplasmic tail to
invasive and metastatic properties of a pancreatic cancer cell
line. Cancer Res. 63:5011–5020. 2003.PubMed/NCBI
|
|
31
|
Inagaki Y, Tang W, Xu H, et al: Sustained
aberrant localization of KL-6 mucin and beta-catenin at the
invasion front of human gastric cancer cells. Anticancer Res.
31:535–542. 2011.PubMed/NCBI
|
|
32
|
Bozkaya G, Korhan P, Cokakli M, et al:
Cooperative interaction of MUC1 with the HGF/c-Met pathway during
hepatocarcinogenesis. Mol Cancer. 11:642012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan SF, Li KZ, Wang L, et al: Expression
of MUC1 and its significance in hepatocellular and
cholangiocarcinoma tissue. World J Gastroenterol. 11:4661–4666.
2005.PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
35
|
Veeravalli KK, Chetty C, Ponnala S, et al:
MMP-9, uPAR and cathepsin B silencing downregulate integrins in
human glioma xenograft cells in vitro and in vivo in nude mice.
PLoS One. 5:e115832010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang F, Li Q, Ni W, et al: Expression of
human full-length MUC1 inhibits the proliferation and migration of
a B16 mouse melanoma cell line. Oncol Rep. 30:260–268.
2013.PubMed/NCBI
|
|
37
|
Costa NR, Paulo P, Caffrey T,
Hollingsworth MA and Santos-Silva F: Impact of MUC1 mucin
downregulation in the phenotypic characteristics of MKN45 gastric
carcinoma cell line. PLoS One. 6:e269702011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsutsumida H, Swanson BJ, Singh PK, et al:
RNA interference suppression of MUC1 reduces the growth rate and
metastatic phenotype of human pancreatic cancer cells. Clin Cancer
Res. 12:2976–2987. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raina D, Kharbanda S and Kufe D: The MUC1
oncoprotein activates the anti-apoptotic phosphoinositide
3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol
Chem. 279:20607–20612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Raina D, Ahmad R, Chen D, Kumar S,
Kharbanda S and Kufe D: MUC1 oncoprotein suppresses activation of
the ARF-MDM2-p53 pathway. Cancer Biol Ther. 7:1959–1967. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Agata N, Ahmad R, Kawano T, Raina D,
Kharbanda S and Kufe D: MUC1 oncoprotein blocks death
receptor-mediated apoptosis by inhibiting recruitment of caspase-8.
Cancer Res. 68:6136–6144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ahmad R, Alam M, Rajabi H and Kufe D: The
MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX
protein and blocks BAX function. J Biol Chem. 287:20866–20875.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Liu D, Chen D, Kharbanda S and Kufe
D: Human DF3/MUC1 carcinoma-associated protein functions as an
oncogene. Oncogene. 22:6107–6110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wen Y, Caffrey TC, Wheelock MJ, Johnson KR
and Hollingsworth MA: Nuclear association of the cytoplasmic tail
of MUC1 and beta-catenin. J Biol Chem. 278:38029–38039. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Yi H, Yao Y, et al: The cytoplasmic
domain of MUC1 induces hyperplasia in the mammary gland and
correlates with nuclear accumulation of beta-catenin. PLoS One.
6:e191022011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yuan Z, Wong S, Borrelli A and Chung MA:
Downregulation of MUC1 in cancer cells inhibits cell migration by
promoting E-cadherin/catenin complex formation. Biochem Biophys Res
Commun. 362:740–746. 2007. View Article : Google Scholar : PubMed/NCBI
|
